Mandate

Vinge advises Air Liquide Santé International on the acquisition of NordicInfu Care AB

March 11, 2013

Vinge is advising Air Liquide Santé International in connection with its acquisition of NordicInfu Care AB. Air Liquide Santé International is Europe’s leading and the world’s third largest company within home healthcare and provides treatment for patients with chronic diseases, such as Parkinson, COPD (Chronic Obstructive Pulmonary Disease) and diabetes. Air Liquide Santé International posted revenues of EUR 2.5 billion in 2012 and has 10,000 employees. Air Liquide Santé International is a division within the publicly listed French group Air Liquide.

NordicInfu Care AB is a leading company in the Nordic countries within home infusion therapy for patients with chronic diseases such as Parkinson, PAH (Pulmonary Arterial Hypertension) and diabetes and had a turnover in 2012 of approximately EUR 22 million. Through the acquisition, Air Liquide Santé International expands its home healthcare activities to the Nordic market, where presence up until now has been limited.

The Vinge team advising Air Liquide Santé International includes partner Jesper Ottergren and associate Ida Christiansson. Furthermore, among others, associates Lynn Andersson Wall and Charlotta Cronér (employment law), Rickard Vernet (competition law), Johan Cederblad (regulatory matters) and counsel Maria Schultzberg (tax) have assisted in the transaction.

Related

Vinge advises OsteoCentric on the public offer for Integrum

OsteoCentric Oncology and Bone Anchored Prostheses, LLC, a subsidiary of OsteoCentric Technologies, Inc., has made a public offer for all shares in Integrum AB (publ). The offer values all shares in Integrum at approximately SEK 939 million.
July 23, 2025

Vinge advises Investor on its co-investment in the SEK 55 billion public offer for Fortnox led by EQT X

Vinge advises Investor AB (publ) (“Investor”) on its co-investment in the public offer for Fortnox AB (publ) (“Fortnox”) led by EQT X together with First Kraft AB (owned by Olof Hallrup), acting through Omega II AB (“Omega II”). Fortnox offers vital software infrastructure to small and medium-sized companies in Sweden with a track record of profitable growth.
July 22, 2025

Vinge advises Cantargia in connection with the sale of immunology program CAN10

Vinge advises Cantargia AB (publ) in connection with the sale of its early-clinical stage IL1RAP immunology program CAN10 to the Japanese healthcare company Otsuka Pharmaceutical.
July 21, 2025